| TA100 |
Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100) |
|
-
-
colorectal cancer
Fast, easy summary view of NICE guidance on 'colorectal cancer'
-
-
-
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer
Capecitabine and oxaliplatin are recommended as possible adjuvant treatments after surgery for stage III (Dukes’ C) colon cancer, when used in the following ways:
- capecitabine on its own
- oxaliplatin together with 5-fluorouracil and folinic acid.
The choice of treatment should be decided jointly by the individual and their doctors, after they have discussed the options. This discussion should cover any contraindications to the treatments (reasons why a particular medicine might not be suitable for the person), the possible side effects of the treatments, and the different ways they can be given. It should also take into account the person’s clinical condition and individual preferences.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: colorectal cancer
How this guidance was produced
Background information
This page was last updated: 12 December 2011
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
